Galderma Group AG Registered Shares GALD

Morningstar Rating
CHF 77.33 +1.27 (1.67%)
View Full Chart

Company Report

Galderma's Diversified Dermatology Portfolio and Drug Pipeline Support Positive Outlook

Galderma is a pure-play dermatology company, with a leadership position in the self-care segment of the market, with more than 90% of total sales paid by consumers out of pocket. Its long-term revenue growth is supported by changing consumer behavior and perception around skin health and appearance. The company deploys an omnichannel go-to-market strategy, supported by a specialized, high-touch salesforce of over 1,900 employees reaching more than 110,000 healthcare professionals. This is complemented by a leading presence at dermatology congresses and an emphasis on educational, training, and loyalty programs to reinforce physician entrenchment.

Price vs Fair Value

GALD is trading at a 335% premium.
Price
CHF 76.06
Fair Value
CHF 32.00
Uncertainty
Medium
1-Star Price
CHF 282.38
5-Star Price
CHF 94.30
Economic Moat
Xfjqrt
Capital Allocation
Gkdwgcjm

Bulls Say, Bears Say

Bulls

Galderma’s sizable innovation pipeline should translate into accelerated revenue growth and EBITDA margin accretion over the midterm.

Bears

The agreement with Ipsen for the current neuromodulator portfolio features stepped royalties that have been weighing on margins and may limit the company in pursuing volume market share growth.

News

Trading Information

Previous Close Price
CHF 76.06
Day Range
CHF 76.2477.82
52-Week Range
CHF 60.0084.92
Bid/Ask
CHF 77.33 / CHF 77.38
Market Cap
CHF 18.37 Bil
Volume/Avg
30,833 / 631,261

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield

Company Profile

Galderma was formed in 1981 as a joint venture between Nestle and L’Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma’s science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Large Growth
Total Number of Employees

Competitors

Valuation

Metric
GALD
ABBV
OR
Price/Earnings (Normalized)
18.3929.99
Price/Book Value
2.6351.287.12
Price/Sales
6.344.95
Price/Cash Flow
18.6726.01
Price/Earnings
GALD
ABBV
OR

Financial Strength

Metric
GALD
ABBV
OR
Quick Ratio
0.910.590.57
Current Ratio
1.200.811.01
Interest Coverage
3.5125.91
Quick Ratio
GALD
ABBV
OR

Profitability

Metric
GALD
ABBV
OR
Return on Assets (Normalized)
13.66%12.72%
Return on Equity (Normalized)
189.99%22.90%
Return on Invested Capital (Normalized)
27.06%16.77%
Return on Assets
GALD
ABBV
OR

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
YbwpphtrxYmxf$87.2 Bil
Merck KGaA ADR
MKKGY
RvbjxfmjYgjyyk$75.7 Bil
Haleon PLC ADR
HLN
TdzbtqyTpgb$47.3 Bil
Teva Pharmaceutical Industries Ltd ADR
TEVA
TzrtvxybYds$20.0 Bil
Viatris Inc
VTRS
ZgdltnsxDzvxw$13.7 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
McnvtwnFywrc$13.4 Bil
Catalent Inc
CTLT
MslkkkkwkFynjm$11.0 Bil
Prestige Consumer Healthcare Inc
PBH
RccyqxnYvpldc$3.5 Bil
Perrigo Co PLC
PRGO
ZybxmljpHlmbm$3.4 Bil
Green Thumb Industries Inc
GTBIF
QxxnkkrcLypq$2.4 Bil

Sponsor Center